Novartis’s ‘Poster Child’ Zolgensma Shows What Gene Therapy Can Do – And Its Limitations

Long-Term Data Brings Hope To Rare Disease Communities

 
• By Andrew McConaghie
Zolgensma Glove
Zolgensma is currently the most successful AAV-based gene therapy on the market. • Source: Shutterstock

More from Business

More from Scrip